ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Indian biotechnology firm Biocon has emerged as the winning bidder for the assets of Research Triangle Park, N.C.-based Nobex, which declared bankruptcy in December. After submitting an opening bid of $3.5 million, Biocon finally captured the assets for $5 million. Biocon gains access to Nobex's alkylPEGylation technology for conjugating polymers to drug molecules, as well as the full rights to oral insulin and calcitonin drugs. Nobex and Biocon teamed up to develop Nobex's oral insulin in 2004, a year after GlaxoSmithKline, Nobex's original partner for the drug, backed out of their alliance.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter